SynthesisFrontiers in oncology2026
KRAS
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The KRAS Methods: A comprehensive literature search was undertaken across six databases to identify phase 3 randomized controlled trials (RCTs) evaluating KGIs versus conventional chemotherapy. Progression-free survival (PFS) was the primary endpoint, while secondary endpoints included central nervous system (CNS)-PFS, treatment responses, and treatment-related adverse events (TRAEs). Results: Two phase 3 RCTs (CodeBreaK 200 and KRYSTAL-12) involving 798 patients were included. The meta-analysis showed that KGIs significantly improved PFS (HR: 0.62 [0.51, 0.74], P < 0.00001) and CNS-PFS (HR: 0.55 [0.32, 0.94], P = 0.03). The survival rates of PFS at 1-12 months were also improved in the KGI group. Subgroup analyses demonstrated a consistent PFS benefit of KGIs over chemotherapy across all predefined subgroups. The objective response rate (ORR, RR: 2.73 [1.93, 3.85], P < 0.00001) and disease control rate (DCR, RR: 1.35 [1.22, 1.50], P < 0.00001) were also higher in the KGI group. Total and grade 3-5 TRAEs were similar between groups, although more TRAEs leading to dose interruption were observed in the KGI group (RR: 3.13 [2.37, 4.13], P < 0.00001). The top 3 grade 3-5 TRAEs in the KGI group were diarrhea (7.63%), alanine aminotransferase increased (7.63%), and aspartate aminotransferase increased (5.93%). Conclusion: KGIs demonstrated superior PFS, CNS-PFS, and response rates, with a manageable toxicity profile, suggesting that they represent a preferred treatment option for this population. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251272701, identifier CRD420251272701.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.